

## *Shilpa Medicare Limited*

### **Corporate & Admin Office:**

“Shilpa House”, # 12-6-214/A-1, Hyderabad Road,  
Raichur – 584 135, Karnataka, India  
Tel: +91-8532-238704, Fax: +91-8532-238876  
Email: info@vbshilpa.com, Web: www.vbshilpa.com  
CIN: L85110KA1987PLC008739

02 May 2022

To  
Corporate Relationship Department,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai-400 001

To  
National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No.C/1, G Block  
Bandra Kurla Complex, Bandra (E)  
Mumbai – 400 051.

Dear Sir/Ma'am,

**Sub: US FDA Inspection of Shilpa Medicare Limited, Unit VII, Analytical Services Division**

**Ref: Intimation U/R 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Scrip Code: 530549/ Stock Symbol: SHILPAMED

This is to inform you that the Company's recently started Analytical Services Division situated on first Floor of Unit 7, Nacharam, Hyderabad, Telangana was inspected by US FDA during 26 Apr 2022 to 29 Apr 2022.

The inspection was triggered by Shilpa's submission of applications for four ANDA's to seek approval to use this site as alternate testing laboratory. The inspection has been closed with four observations, which are related to improvements in existing procedures and are addressable.

The Company will be submitting the responses to US FDA observations within stipulated timeline and implement the corrective actions to address the observations.

This Analytical Services Division has started analytical testing operations from May 2021. This is the first US FDA inspection of this facility. The facility is involved in analytical testing of drug products, drug substances, raw materials & packing materials. It is also engaged in analytical method validations, method transfers and conduct of other miscellaneous studies. This facility has not been used till now to test products for commercial dispatch into US/EU markets.

The Exchange is requested to take the same on record and disseminate the information to stakeholders of the Company.

Thanking you,

Yours Sincerely,

For **Shilpa Medicare Limited**

**Krishnappayya Desai**

**Compliance Officer (Interim)**